Aditxt, Inc. (ADTX)

Aditxt, Inc. is a biotechnology company incorporated in 2017 and headquartered in Richmond, Virginia. It was originally named ADiTx Therapeutics and adopted the Aditxt name in July 2021. The company described its mission as monitoring and reprogramming the immune system.

Its first commercial offering, AditxtScore, was an immune monitoring platform intended to help individuals understand how their immune systems respond to threats such as pathogens and to their own tissues. The company also developed Apoptotic DNA Immunotherapy, a nucleic acid approach intended to induce tolerance in autoimmune disease, allergy and organ transplantation, and had license agreements with Loma Linda University and Stanford University.

Aditxt completed its initial public offering and listed on Nasdaq under the symbol ADTX in 2020. The company recorded persistent operating losses and relied on frequent equity and debt financings. To maintain its minimum bid price it carried out multiple reverse stock splits over several years.

In 2026 Nasdaq staff determined that the stock failed the $1.00 minimum bid price requirement. Because the company had effected reverse splits totaling 250 to 1 or more over the prior two years, it was ineligible for a compliance period. Its Form 10-Q for the quarter ended March 31, 2026 also reported stockholders' deficit of about $35 million, well below the $2.5 million minimum stockholders' equity requirement.

A Nasdaq hearings panel held a hearing on June 11, 2026 and notified the company on June 23 that its request for continued listing had been denied. Trading was suspended at market open on June 25, 2026, and the shares moved to the over-the-counter market.

A Form 25 was filed with the SEC in early October 2026, and the removal from listing took effect shortly thereafter. The delisting resulted from noncompliance with exchange rules and was not an acquisition, so no consideration was paid to shareholders.